Position in NAMS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$340,967
New position
Shares Held
10,061
first reported quarter
Ownership
0.008%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#138
of 197 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 99%
Shared 0%
None 1%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Cerity Partners LLC holds $424,897,823 across 139 Biotechnology names. NAMS ranks #80 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
255,874 | $127,100,291 | |
| 2 | CORT |
Corcept Therapeutics Inc
|
797,119 | $69,309,495 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
343,589 | $26,892,710 | |
| 4 | REGN |
Regeneron Pharmaceuticals, Inc.
|
39,274 | $24,488,909 | |
| 5 | INCY |
Incyte Corp
|
205,071 | $23,246,847 | |
| 6 | EXEL |
Exelixis, Inc.
|
377,130 | $20,519,642 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
53,534 | $12,900,087 | |
| 8 | RPRX |
Royalty Pharma plc
|
180,772 | $10,135,884 |
All Filings in NAMS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $340,967 | 10,061 | Shares | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||